OncoMatch

OncoMatch/Clinical Trials/NCT06793241

Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia

Is NCT06793241 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells for b-cell acute lymphoblastic leukemia.

Early Phase 1RecruitingZhejiang UniversityNCT06793241Data as of May 2026

Treatment: CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cellsA Clinical Study on the Safety and Effectiveness of donor derived CD19 CAR-T Cells in the treatment of R/R B-cell acute lymphoblastic leukemia

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: CD19 positive (positive)

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: chemotherapy — standard or remedial

No CR was obtained after standard chemotherapy; CR was induced for the first time, but the duration of CR was less than 12 months; R/R B-ALL that does not work after the first or more remedial treatments; Two or more relapses

Cannot have received: allogeneic hematopoietic stem cell transplantation

Exception: allowed if ≥100 days since transplant

Less than 100 days after receiving allogeneic hematopoietic stem cell transplantation

Cannot have received: anti-cancer chemotherapy or other drugs

Exception: allowed if >2 weeks prior to screening

Patients who received anti-cancer chemotherapy or other drugs within 2 weeks prior to screening

Lab requirements

Blood counts

Absolute neutrophil count: ≥ 0.5×10^9/L; Platelet: ≥ 30×10^9/L; Hemoglobin ≧60g/L

Kidney function

creatinine ≤176.8 (μmol/L)

Liver function

Total bilirubin ≤51 (μmol/L), ALT/AST ≤ 3 times the upper limit of normal

Cardiac function

Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%

Total bilirubin ≤51 (μmol/L), ALT/AST ≤ 3 times the upper limit of normal, creatinine ≤176.8 (μmol/L); Absolute neutrophil count: ≥ 0.5×10^9/L; Platelet: ≥ 30×10^9/L; Hemoglobin ≧60g/L; Echocardiography showed left ventricular ejection fraction (LVEF) ≥40%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify